论文部分内容阅读
目的探讨新疆地区维吾尔族与汉族前列腺癌患者内分泌治疗敏感时间及其影响内分泌治疗敏感时间的临床因素,为新疆地区前列腺癌患者的个体化治疗提供依据。方法将内分泌治疗至进展为去势抵抗性前列腺癌(CRPC)的时间定义为内分泌治疗敏感时间,回顾性分析111例单纯内分泌治疗的维吾尔族和汉族前列腺癌患者的临床资料,建立Cox回归模型,分析各临床因素和内分泌治疗敏感时间的相关关系。结果单因素分析显示,民族(P=0.508)、年龄(P=0.099)、单纯内分泌治疗方式(P=0.399)与内分泌治疗敏感时间无相关性。而初始PSA、临床分期、Gleason评分、PSA最低值、骨转移情况与内分泌治疗敏感时间存在显著相关关系(P<0.05)。多因素分析显示,仅临床分期(P=0.000)和最低PSA值(P=0.000)是前列腺癌患者内分泌治疗敏感时间的主要影响因素。临床分期越高,内分泌治疗后越早出现CRPC。内分泌治疗后PSA能降至0.2 ng/mL及以下的患者较晚发展为CRPC。结论新疆地区维吾尔族与汉族前列腺癌患者内分泌治疗敏感时间无差异,而临床分期与PSA最低值是前列腺癌内分泌治疗敏感时间的独立危险因素。
Objective To investigate the sensitive time of endocrine therapy in Uygur and Han nationality patients with prostate cancer in Xinjiang region and its clinical factors that affect the sensitive time of endocrine therapy and provide the basis for individualized treatment of prostate cancer patients in Xinjiang region. Methods The time from endocrine therapy to progression-to-resist prostate cancer (CRPC) was defined as the time of endocrine therapy. The clinical data of 111 endocrine-treated Uigur and Han nationality prostate cancer patients were retrospectively analyzed. Cox regression model was established, Analysis of the clinical factors and the relationship between the endocrine treatment of sensitive time. Results Univariate analysis showed no correlation between ethnic (P = 0.508), age (P = 0.099), endocrine therapy alone (P = 0.399) and endocrine therapy-sensitive time. The initial PSA, clinical stage, Gleason score, PSA, bone metastasis and endocrine therapy sensitive time there is a significant correlation (P <0.05). Multivariate analysis showed that only the clinical stage (P = 0.000) and the lowest PSA level (P = 0.000) were the main influencing factors of the endocrine therapy sensitive time in patients with prostate cancer. The higher the clinical stage, the sooner the endocrine therapy appears CRPC. Patients with PSA below 0.2 ng / mL after endocrine therapy develop CRPC later. Conclusion There is no difference in the time of endocrine therapy between Uygur and Han nationality patients in Xinjiang. However, the clinical stage and the lowest PSA level are independent risk factors of endocrine therapy of prostate cancer.